Search Results
You are looking at 1 - 1 of 1 items for
- Author: Sefirin Djiogue x
- Refine by access: All content x
Search for other papers by Sefirin Djiogue in
Google Scholar
PubMed
Department of Animal Biology and Physiology, Biomedical Research Center, Department of Biomedical Sciences, Laboratory of Cytometry, Department of Veterinary Anatomy, Optometry, University of Yaoundé 1, PO Box 812, Yaoundé, Cameroon
Search for other papers by Armel Hervé Nwabo Kamdje in
Google Scholar
PubMed
Search for other papers by Lorella Vecchio in
Google Scholar
PubMed
Search for other papers by Maulilio John Kipanyula in
Google Scholar
PubMed
Search for other papers by Mohammed Farahna in
Google Scholar
PubMed
Search for other papers by Yousef Aldebasi in
Google Scholar
PubMed
Search for other papers by Paul Faustin Seke Etet in
Google Scholar
PubMed
Insulin, IGF1, and IGF2 are the most studied insulin-like peptides (ILPs). These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as associated immune deregulations. A growing body of evidence suggests that insulin and IGF1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus play a pivotal role in cell fate determination. Despite the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation, and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of ILPs as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening and novel approaches to controlling tumor development.
